Reuters -- U.S. drug reviewers have questioned if a proposed leukemia drug from GlaxoSmithKline PLC and Genmab provides enough benefit to warrant approval, documents released on Wednesday said.
Reuters -- U.S. drug reviewers have questioned if a proposed leukemia drug from GlaxoSmithKline PLC and Genmab provides enough benefit to warrant approval, documents released on Wednesday said.
